Searched for
SUVEN PHARMA NET PROFIT
Oyo IPO: How real is Oyo parent PRISM’s Rs 748 crore net profitOyo IPO: PRISM, formerly Oravel Stays, has reported a Rs 748 crore profit for the nine months ending December 31, 2025, a significant turna...- Two Trades for Today: An auto sector major for a 6.25% upmove, a mid-cap pharma stock for a gain of almost 7%Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Hindustan Copper pins Navratna ambitions on 50,000 TPA Jhagadia ProjectHindustan Copper's Jhagadia project in Gujarat, a 50,000-tonne secondary copper smelter, is poised to significantly boost the company's rev...
- Saksoft shares rally 50% in one week. Here's what technical charts indicateSaksoft shares experienced a significant surge, climbing over 14% on Tuesday and an impressive 50% in a single week. This rally follows a d...
- Hindustan Copper to seek Navratna status, eyes threefold ore output by 2029Hindustan Copper is aiming for Navratna status, according to outgoing CMD Sanjiv Kumar Singh. The company plans to triple ore output by 202...
- Market wrap: Sensex falls 372 points, Nifty closes below 23,950; Kotak Mahindra Bank drops 3%Indian markets ended lower as Sensex and Nifty snapped a two-session winning streak, pressured by geopolitical tensions in the Middle East ...
- HAL announces final dividend of Rs 10 for FY26. Check record date and other detailsHAL has declared a final dividend of Rs 10 per share (200%) for FY26, subject to shareholder approval at the upcoming AGM. The record date ...
- 2 top stock recommendations from Vinay RajaniIndian equity markets are experiencing a cautious phase, consolidating within a defined range as fresh buying momentum remains elusive. Tec...
- Nifty has more room to run; stay selective: AnalystsIndian stock markets are showing cautious optimism, with the Nifty eyeing the 24,300-25,000 zone amid ongoing volatility. Analysts recommen...
- Tata Sons back on track in FY26 with ₹32,000 crore net profitTata Sons, the holding company of the Tata Group, reported strong performance in FY26 despite global geopolitical uncertainty, according to...
- F&O Talk: Nifty to remain rangebound, says Sudeep Shah; picks 8 stocks for next weekIndian stock markets concluded the week with modest gains, as Sensex and Nifty erased earlier surges on monthly expiry day. Analysts observ...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- Largecaps lead profit growth, mid & smallcaps outshine in revenue momentum in Q4Large companies saw stronger net profit growth for the March 2026 quarter, driven by one-off gains, despite slower revenue expansion and wi...
- Tech-Led global selloff, Fed rate fears weigh on Indian equitiesIndian stock markets experienced their sharpest single-day drop in nearly a month, mirroring a global tech sell-off. The Nifty 50 and BSE S...
- Ahead of Market: 10 things that will decide stock market action on WednesdaySensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...
- Honasa Consumer to acquire majority stake in Fluence Pharma at Rs 135-crore valuationHonasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...
- Defence valuations 'obnoxious'; private banks look strong: Sandip Sabharwal's full market playbookInvestor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
Load More
